1. Home
  2. DFDV vs IPHA Comparison

DFDV vs IPHA Comparison

Compare DFDV & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DFDV
  • IPHA
  • Stock Information
  • Founded
  • DFDV 2018
  • IPHA 1999
  • Country
  • DFDV United States
  • IPHA France
  • Employees
  • DFDV N/A
  • IPHA N/A
  • Industry
  • DFDV Finance: Consumer Services
  • IPHA Biotechnology: Pharmaceutical Preparations
  • Sector
  • DFDV Finance
  • IPHA Health Care
  • Exchange
  • DFDV Nasdaq
  • IPHA Nasdaq
  • Market Cap
  • DFDV 143.9M
  • IPHA 160.1M
  • IPO Year
  • DFDV N/A
  • IPHA 2019
  • Fundamental
  • Price
  • DFDV N/A
  • IPHA $2.04
  • Analyst Decision
  • DFDV
  • IPHA Strong Buy
  • Analyst Count
  • DFDV 0
  • IPHA 1
  • Target Price
  • DFDV N/A
  • IPHA $11.00
  • AVG Volume (30 Days)
  • DFDV 315.1K
  • IPHA 32.2K
  • Earning Date
  • DFDV 05-23-2025
  • IPHA 03-27-2025
  • Dividend Yield
  • DFDV N/A
  • IPHA N/A
  • EPS Growth
  • DFDV N/A
  • IPHA N/A
  • EPS
  • DFDV N/A
  • IPHA N/A
  • Revenue
  • DFDV $2,099,660.00
  • IPHA $20,831,349.00
  • Revenue This Year
  • DFDV N/A
  • IPHA $209.83
  • Revenue Next Year
  • DFDV N/A
  • IPHA $83.96
  • P/E Ratio
  • DFDV N/A
  • IPHA N/A
  • Revenue Growth
  • DFDV 4.82
  • IPHA N/A
  • 52 Week Low
  • DFDV $3.37
  • IPHA $1.29
  • 52 Week High
  • DFDV $91.38
  • IPHA $3.51
  • Technical
  • Relative Strength Index (RSI)
  • DFDV N/A
  • IPHA 45.40
  • Support Level
  • DFDV N/A
  • IPHA $2.22
  • Resistance Level
  • DFDV N/A
  • IPHA $2.56
  • Average True Range (ATR)
  • DFDV 0.00
  • IPHA 0.16
  • MACD
  • DFDV 0.00
  • IPHA 0.00
  • Stochastic Oscillator
  • DFDV 0.00
  • IPHA 11.86

About DFDV DeFi Development Corp. Common Stock

DeFi Development Corp is an AI-powered online platform that connects the commercial real estate industry by providing data and software subscriptions as well as value-add services to multifamily and commercial property professionals.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Share on Social Networks: